Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Should active injecting drug users receive treatment for chronic hepatitis C?

Arquivos de gastroenterologia - 1 Jan 2000

Papadopoulos Vasileios, Gogou Aikaterini, Mylopoulou Theodora, Mimidis Konstantinos

Abstract excerpt

CONTEXT: Accumulating data propose that active injecting drug users might not differ from the general population in terms of sustained virological response when adherent to therapy for chronic hepatitis C. However, current guidelines contain restrictive recommendations for therapy in this group of patients. OBJECTIVE: Therefore, we evaluated a cohort of chronic hepatitis C patients regarding the potent influence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Medication Adherence

Share to Ribavirin

Share to Socioeconomic Factors

Share to Substance Abuse, Intravenous

Source

Identifiers

PMID: 21140082
DOI: 10.1590/s0004-28032010000300005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Should active injecting drug users receive treatment for chronic hepatitis C?PMID 21140082Read ↗

Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C.Semantic proximity Read ↗

Characteristics of chronic hepatitis C among intravenous drug users: a comparative analysis.Semantic proximity Read ↗

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.Semantic proximity Read ↗

High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.Semantic proximity Read ↗

Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users.Semantic proximity Read ↗

Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.Semantic proximity Read ↗

Hepatitis C infection: eligibility for antiviral therapies.Semantic proximity Read ↗

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.Semantic proximity Read ↗

Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.Semantic proximity Read ↗

Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.Semantic proximity Read ↗

Hepatitis C in an urban cohort: who's not being treated?Semantic proximity Read ↗

Hepatitis C virus infection among drug addicts in Italy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.